Pharmacotherapeutic considerations for the management of cardiovascular diseases among hospitalized COVID-19 patients

References

• Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020;20(5):533–534.
   PubMed Web of Science ®Google Scholar
• Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area . JAMA. 2020;323(20):2052–2059. [published online ahead of print, 2020 Apr 22].
   PubMed Web of Science ®Google Scholar
• Yang J, Zheng Y, Gou X, et al. Prevalence of comorbidities and its effects in coronavirus disease 2019 patients: a systematic review and meta-analysis . Int J Infect Dis. 2020;94:91–95. [published online ahead of print, 2020 Mar 12]
   PubMed Web of Science ®Google Scholar
• Guan WJ, Liang WH, Zhao Y, et al. Comorbidity and its impact on 1590 patients with Covid-19 in China: a nationwide analysis . Eur Respir J. 2020;55(5):2000547. [published online ahead of print, 2020 Mar 26]
   PubMed Web of Science ®Google Scholar
• Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the american college of cardiology/American heart association task force on clinical practice guidelines. Hypertension. 2018;71:e13.
   PubMed Web of Science ®Google Scholar
• Unger T, Borghi C, Charchar F, et al. International society of hypertension global hypertension practice guidelines. Hypertension. 2020;38(6):982–1004.
   Google Scholar
• Williams B, Mancia G, Spiering W, et al. ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021.
   PubMed Web of Science ®Google Scholar
• Turnbull F, Neal B, Ninomiya T, et al. Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ. 2008;336:1121.
   PubMed Web of Science ®Google Scholar
• Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338(may19 1):b1665.
   PubMedGoogle Scholar
• Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387(10022):957.
   PubMed Web of Science ®Google Scholar
• Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–1720. [published online ahead of print, 2020 Feb 28].
   Web of Science ®Google Scholar
• Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020;75(7):1730–1741. [published online ahead of print, 2020 Feb 19].
   Web of Science ®Google Scholar
• Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;S0140-6736(20):30566. [published online ahead of print, 2020 Mar 11] [published correction appears in Lancet. 2020 Mar 12;:].
   Google Scholar
• Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China . JAMA Intern Med. 2020;180(7):1–11. [published online ahead of print, 2020 Mar 13].
   Web of Science ®Google Scholar
• Shi S, Qin M, Shen B, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China . JAMA Cardiol. 2020;5(7):802–810. [published online ahead of print, 2020 Mar 25].
   PubMed Web of Science ®Google Scholar
• Guo T, Fan Y, Chen M, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19) . JAMA Cardiol. 2020;5(7):1–8. [published online ahead of print, 2020 Mar 27].
   Web of Science ®Google Scholar
• Zheng YY, Ma YT, Zhang JY, et al. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020;17(5):259–260. [published online ahead of print, 2020 Mar 5].
   Web of Science ®Google Scholar
• Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020;S2213-2600(20): 30116–30118. [published online ahead of print, 2020 Mar 11].
   Google Scholar
• Ishiyama Y, Gallagher PE, Averill DB, et al. Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension. 2004;43(5):970–976.
   PubMed Web of Science ®Google Scholar
• Ocaranza MP, Godoy I, Jalil JE, et al. Enalapril attenuates downregulation of Angiotensin-converting enzyme 2 in the late phase of ventricular dysfunction in myocardial infarcted rat. Hypertension. 2006;48(4):572–578.
   PubMed Web of Science ®Google Scholar
• Soler MJ, Ye M, Wysocki J, et al. Localization of ACE2 in the renal vasculature: amplification by angiotensin II type 1 receptor blockade using telmisartan. Am J Physiol Renal Physiol. 2009;296(2):F398–F405.
   PubMed Web of Science ®Google Scholar
• Ferrario CM, Jessup J, Chappell MC, et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation. 2005;111(20):2605–2610.
   PubMed Web of Science ®Google Scholar
• Zhong JC, Ye JY, Jin HY, et al. Telmisartan attenuates aortic hypertrophy in hypertensive rats by the modulation of ACE2 and profilin-1 expression. Regul Pept. 2011;166(1–3):90–97.
   PubMedGoogle Scholar
• Klimas J, Olvedy M, Ochodnicka-Mackovicova K, et al. Perinatally administered losartan augments renal ACE2 expression but not cardiac or renal Mas receptor in spontaneously hypertensive rats. J Cell Mol Med. 2015;19(8):1965–1974.
   PubMed Web of Science ®Google Scholar
• Furuhashi M, Moniwa N, Mita T, et al. Urinary angiotensin-converting enzyme 2 in hypertensive patients may be increased by olmesartan, an angiotensin II receptor blocker. Am J Hypertens. 2015;28(1):15–21.
   PubMed Web of Science ®Google Scholar
• Vuille-dit-Bille RN, Camargo SM, Emmenegger L, et al. Human intestine luminal ACE2 and amino acid transporter expression increased by ACE-inhibitors. Amino Acids. 2015;47(4):693–705.
   PubMed Web of Science ®Google Scholar
• Hristova M, Stanilova S, Miteva L. Serum concentration of renin-angiotensin system components in association with ACE I/D polymorphism among hypertensive subjects in response to ACE inhibitor therapy. Clin Exp Hypertens. 2019;41(7):662–669.
   PubMed Web of Science ®Google Scholar
• Burrell LM, Risvanis J, Kubota E, et al. Myocardial infarction increases ACE2 expression in rat and humans. Eur Heart J. 2005;26(4):324–369.
   Web of Science ®Google Scholar
• Burchill LJ, Velkoska E, Dean RG, et al. Combination renin-angiotensin system blockade and angiotensin-converting enzyme 2 in experimental myocardial infarction: implications for future therapeutic directions. Clin Sci (Lond). 2012;123(11):649–658.
   PubMed Web of Science ®Google Scholar
• Kuba K, Imai Y, Rao S, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med. 2005;11(8):875–879.
   PubMed Web of Science ®Google Scholar
• Imai Y, Kuba K, Rao S, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 2005;436(7047):112–116.
   PubMed Web of Science ®Google Scholar
• Li J, Wang X, Chen J, et al. Association of renin-angiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for coronavirus disease 2019 (COVID-19) infection in Wuhan, China. JAMA Cardiol. 2020;5(7):825. [published online ahead of print, 2020 Apr 23].
   Web of Science ®Google Scholar
• Zhang P, Zhu L, Cai J, et al. Association of inpatient use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circ Res. 2020. [published online ahead of print, 2020 Apr 17]. DOI:10.1161/CIRCRESAHA.120.317134.
   Web of Science ®Google Scholar
• Reynolds HR, Adhikari S, Pulgarin C, et al. Renin-angiotensin-aldosterone system inhibitors and risk of COVID-19. N Engl J Med . 2020;382(25):2441–2448. [published online ahead of print, 2020 May 1].
   Web of Science ®Google Scholar
• Fosbøl EL, Butt JH, Østergaard L, et al. Association of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use with COVID-19 diagnosis and mortality . JAMA. 2020;;324(2):168–177. [published online ahead of print, 2020 Jun 19].
   Web of Science ®Google Scholar
• Kow CS, Zaidi STR, Hasan SS. Cardiovascular disease and use of renin-angiotensin system inhibitors in COVID-19. Am J Cardiovasc Drugs. 2020;20(3):217–221. [published online ahead of print, 2020 Apr 13]. DOI: 10.1007/s40256-020-00406-0. .
   PubMed Web of Science ®Google Scholar
• Zhang L, Sun Y, Zeng H, et al. Calcium channel blocker amlodipine besylate is associated with reduced case fatality rate of COVID-19 patients with hypertension. medRxiv. ;2020.04.08.20047134.
   Google Scholar
• Solaimanzadeh I. Nifedipine and amlodipine are associated with improved mortality and decreased risk for intubation and mechanical ventilation in elderly patients hospitalized for COVID-19. Cureus. 2020;12(5):e8069.
   PubMed Web of Science ®Google Scholar
• Amsterdam EA, Wenger NK, Brindis RG, et al. AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American college of cardiology/American heart association task force on practice guidelines. J Am Coll Cardiol. 2014;64(24):e139.
   PubMed Web of Science ®Google Scholar
• Roffi M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the european society of cardiology (ESC). Eur Heart J. 2016;37:267.
   PubMed Web of Science ®Google Scholar
• O’Gara PT, Kushner FG, Ascheim DD, et al. ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American college of cardiology foundation/American heart association task force on practice guidelines. Circulation. 2013;127(4):e362.
   PubMed Web of Science ®Google Scholar
• Fihn SD, Blankenship JC, Alexander KP, et al. ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the american college of cardiology/American heart association task force on practice guidelines, and the American association for thoracic surgery, preventive cardiovascular nurses association, society for cardiovascular angiography and interventions, and society of thoracic surgeons. J Am Coll Cardiol. 2014;2014(64):1929.
   Google Scholar
• Lippi G, Plebani M, Henry BM. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a meta-analysis. Clin Chim Acta. 2020;506:145–148.
   PubMed Web of Science ®Google Scholar
• McCarthy CP, Steg G, Bhatt DL. The management of antiplatelet therapy in acute coronary syndrome patients with thrombocytopenia: a clinical conundrum. Eur Heart J. 2017;38(47):3488–3492.
   PubMed Web of Science ®Google Scholar
• Yuan S. Statins may decrease the fatality rate of middle east respiratory syndrome infection. mBio. 2015;6(4):e01120.
   PubMed Web of Science ®Google Scholar
• Yuan X, Deng Y, Guo X, et al. Atorvastatin attenuates myocardial remodeling induced by chronic intermittent hypoxia in rats: partly involvement of TLR-4/MYD88 pathway. Biochem Biophys Res Commun. 2014;446(1):292–297.
   PubMed Web of Science ®Google Scholar
• Totura AL, Whitmore A, Agnihothram S, et al. Toll-like receptor 3 signaling via TRIF contributes to a protective innate immune response to severe acute respiratory syndrome coronavirus infection. mBio. 2015;6(3):e00638–15.
   PubMed Web of Science ®Google Scholar
• Li YH, Wang QX, Zhou JW, et al. Effects of rosuvastatin on expression of angiotensin-converting enzyme 2 after vascular balloon injury in rats. J Geriatr Cardiol. 2013;10(2):151–158.
   PubMedGoogle Scholar
• Shresta S. Statin drug therapy may increase COVID-19 infection. Nepal Med J. 2020;3(1). Epub ahead of print.
   Google Scholar
• Thorp EB, Gallagher TM. Requirements for CEACAMs and cholesterol during murine coronavirus cell entry. J Virol. 2004;78(6):2682–2692.
   PubMed Web of Science ®Google Scholar
• Goldstein MR, Poland GA, Graeber CW. Are certain drugs associated with enhanced mortality in COVID-19? QJM. 2020;113(7):509–510. [published online ahead of print, 2020 Mar 27].
   Web of Science ®Google Scholar
• Rogers A, Guan J, Trtchounian A, et al. Association of elevated plasma interleukin-18 level with increased mortality in a clinical trial of statin treatment for acute respiratory distress syndrome. Crit Care Med. 2019;47(8):1089–1096.
   PubMed Web of Science ®Google Scholar
• Kaplanski G. Interleukin-18: biological properties and role in disease pathogenesis. Immunol Rev. 2018;281(1):138–153.
   PubMed Web of Science ®Google Scholar
• Yamagami H, Sakaguchi M, Furukado S, et al. Statin therapy increases carotid plaque echogenicity in hypercholesterolemic patients. Ultrasound Med Biol. 2008;34(9):1353–1359.
   PubMed Web of Science ®Google Scholar
• Zhang XJ, Qin JJ, Cheng X, et al. In-hospital use of statins is associated with a reduced risk of mortality among individuals with COVID-19. Cell Metab. 2020;S1550-4131(20):30316–30318. [published online ahead of print, 2020 Jun 24].
   Google Scholar
• Baldassarre D, Porta B, Camera M, et al. Markers of inflammation, thrombosis and endothelial activation correlate with carotid IMT regression in stable coronary disease after atorvastatin treatment. Nutr Metab Cardiovasc Dis. 2009;19(7):481–490.
   PubMed Web of Science ®Google Scholar
• Cai Q, Huang D, Yu H, et al. COVID-19: abnormal liver function tests. J Hepatol. 2020;S0168-8278(20):30218–X. [published online ahead of print, 2020 Apr 13].
   Google Scholar
• Cohen DE, Anania FA, Chalasani N, National Lipid Association Statin Safety Task Force Liver Expert Panel. An assessment of statin safety by hepatologists. Am J Cardiol. 2006;97(8):77C.
   PubMedGoogle Scholar
• Vasanthakumar N. Can beta-adrenergic blockers be used in the treatment of COVID-19? . Med Hypotheses. 2020;142:109809; [published online ahead of print, 2020 May 5].
   PubMed Web of Science ®Google Scholar
• Al-Qadi MO, Kashyap R. Effect of chronic beta blockers use on sepsis-related acute respiratory distress syndrome. Am J Respir Crit Care Med. 2015;191:A1602.
   Google Scholar
• Noveanu M, Breidthardt T, Reichlin T, et al. Effect of oral ß-blocker on short and long-term mortality in patients with acute respiratory failure: results from the BASEL-II-ICU study. Crit Care. 2010;14(6):R198.
   PubMed Web of Science ®Google Scholar
• Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE inhibitor myocardial infarction collaborative group.. Circulation. 1998;97(22):2202–2212.
   PubMed Web of Science ®Google Scholar
• Imam Z, Odish F, Gill I, et al. Older age and comorbidity are independent mortality predictors in a large cohort of 1305 COVID-19 patients in Michigan, United States. J Intern Med. 2020. [published online ahead of print, 2020 Jun 4]. DOI:10.1111/joim.13119.
   PubMedGoogle Scholar
• Fried JA, Ramasubbu K, Bhatt R, et al. The variety of cardiovascular presentations of COVID-19. Circulation. 2020;141(23):1930–1936. [published online ahead of print, 2020 Apr 3].
   Web of Science ®Google Scholar
• Kiang MV, Humphreys K, Cullen MR. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020;368:m1091.
   PubMedGoogle Scholar
• Yancy CW, Jessup M, Bozkurt B, et al. ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American college of cardiology/American heart association task force on clinical practice guidelines and the heart failure society of America. Circulation. 2017;136(6):e137.
   PubMed Web of Science ®Google Scholar
• Ponikowski P, Voors AA, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European society of cardiology (ESC)Developed with the special contribution of the heart failure association (HFA) of the ESC. Eur Heart J. 2016;37:2129.
   PubMed Web of Science ®Google Scholar
• Desai AS, Solomon SD, Shah AM, et al. Effect of sacubitril-valsartan vs enalapril on aortic stiffness in patients with heart failure and reduced ejection fraction: a randomized clinical trial. JAMA. 2019;322(11):1–10.
   Web of Science ®Google Scholar
• Mann DL, Barger PM, Burkhoff D. Myocardial recovery and the failing heart: myth, magic, or molecular target? J Am Coll Cardiol. 2012;60(24):2465.
   PubMed Web of Science ®Google Scholar
• Hartupee J, Mann DL. Neurohormonal activation in heart failure with reduced ejection fraction. Nat Rev Cardiol. 2017;14(1):30.
   PubMed Web of Science ®Google Scholar
• Ferrario CM, Ahmad S, Varagic J, et al. Intracrine angiotensin II functions originate from noncanonical pathways in the human heart. Am J Physiol Heart Circ Physiol. 2016;311(2):H404.
   PubMed Web of Science ®Google Scholar
• Bristow MR. beta-adrenergic receptor blockade in chronic heart failure. Circulation. 2000;101(5):558.
   PubMed Web of Science ®Google Scholar
• Joseph P, Swedberg K, Leong DP, et al. The evolution of β-blockers in coronary artery disease and heart failure (Part 1/5). J Am Coll Cardiol. 2019;74(5):672.
   PubMed Web of Science ®Google Scholar
• Lippi G, South AM, Henry BM. Electrolyte imbalances in patients with severe coronavirus disease 2019 (COVID-19) . Ann Clin Biochem. 2020;57(3):262–265. [published online ahead of print, 2020 May 3].
   PubMed Web of Science ®Google Scholar
• Leden I. Digoxin-hydroxychloroquine interaction? Acta Med Scand. 1982;211(5):411–412.
   PubMedGoogle Scholar
• Hayeshi R, Masimirembwa C, Mukanganyama S, et al. The potential inhibitory effect of antiparasitic drugs and natural products on P-glycoprotein mediated efflux. Eur J Pharm Sci. 2006;29(1):70–81.
   PubMed Web of Science ®Google Scholar
• January CT, Wann LS, Calkins H, et al. AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American college of cardiology/American heart association task force on clinical practice guidelines and the heart rhythm society in collaboration with the society of thoracic surgeons. Circulation. 2019;140(21):e125.
   PubMedGoogle Scholar
• Hughes CA, Freitas A, Miedzinski LJ. Interaction between lopinavir/ritonavir and warfarin. CMAJ. 2007;177(4):357–359.
   PubMed Web of Science ®Google Scholar
• Fulco PP, Zingone MM, Higginson RT. Possible antiretroviral therapy-warfarin drug interaction. Pharmacotherapy. 2008;28(7):945–949.
   PubMed Web of Science ®Google Scholar
• Bonora S, Lanzafame M, D’Avolio A, et al. Drug interactions between warfarin and efavirenz or lopinavir-ritonavir in clinical treatment. Clin Infect Dis. 2008;46(1):146–147.
   PubMed Web of Science ®Google Scholar
• Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020;382(19):1787–1799.
   PubMed Web of Science ®Google Scholar
• Yeh RF, Gaver VE, Patterson KB, et al. Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers. J Acquir Immune Defic Syndr. 2006;42(1):52–60.
   PubMed Web of Science ®Google Scholar
• Hasan SS, Kow CS, Merchant H. Is it worth the wait? Should chloroquine or hydroxychloroquine be allowed for immediate use in CoViD-19? Br J Pharm. 2020 Mar 31;5(1):745.
   Google Scholar
• Lane G. Increased hypoprothrombinemic effect of warfarin possibly induced by azithromycin. Ann Pharmacother. 1996;30(7–8):884–885.
   PubMed Web of Science ®Google Scholar
• Woldtvedt BR, Cahoon CL, Bradley LA, et al. Possible increased anticoagulation effect of warfarin induced by azithromycin. Ann Pharmacother. 1998;32(2):269–270.
   PubMed Web of Science ®Google Scholar
• Foster DR, Milan NL. Potential interaction between azithromycin and warfarin. Pharmacotherapy. 1999;19(7):902–908.
   PubMed Web of Science ®Google Scholar
• Rao KB, Pallaki M, Tolbert SR, et al. Enhanced hypoprothrombinemia with warfarin due to azithromycin. Ann Pharmacother. 2004;38(6):982–985.
   PubMed Web of Science ®Google Scholar
• Hazlewood KA, Fugate SE, Harrison DL. Effect of oral corticosteroids on chronic warfarin therapy. Ann Pharmacother. 2006;40(12):2101–2106.
   PubMed Web of Science ®Google Scholar
• Dowd MB, Vavra KA, Witt DM, et al. Empiric warfarin dose adjustment with prednisone therapy. A randomized, controlled trial. J Thromb Thrombolysis. 2011;31(4):472–477.
   PubMed Web of Science ®Google Scholar
• Gebauer MG, Nyfort-Hansen K, Henschke PJ, et al. Warfarin and acetaminophen interaction. Pharmacotherapy. 2003;23(1):109–112.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Bal-dit-Sollier C, Drouet L, et al. Interaction between acetaminophen and warfarin in adults receiving long-term oral anticoagulants: a randomized controlled trial. Eur J Clin Pharmacol. 2011;67(3):309–314.
   PubMed Web of Science ®Google Scholar
• Parra D, Beckey NP, Stevens GR. The effect of acetaminophen on the international normalized ratio in patients stabilized on warfarin therapy. Pharmacotherapy. 2007;27(5):675–683.
   PubMed Web of Science ®Google Scholar
• Mahé I, Bertrand N, Drouet L, et al. Interaction between paracetamol and warfarin in patients: a double-blind, placebo-controlled, randomized study. Haematologica. 2006;91(12):1621–1627.
   PubMed Web of Science ®Google Scholar
• Rohde LE, de Assis MC, Rabelo ER. Dietary vitamin K intake and anticoagulation in elderly patients. Curr Opin Clin Nutr Metab Care. 2007;10(1):1–5.
   PubMed Web of Science ®Google Scholar
• Mattioli AV, Sciomer S, Cocchi C, et al. Quarantine during COVID-19 outbreak: changes in diet and physical activity increase the risk of cardiovascular disease. Nutr Metab Cardiovasc Dis. 2020;S0939-4753(20): 30213. [published online ahead of print, 2020 May 30].
   Google Scholar
• Tian Y, Rong L, Nian W, et al. Review article: gastrointestinal features in COVID-19 and the possibility of faecal transmission. Aliment Pharmacol Ther. 2020;51(9):843–851.
   PubMed Web of Science ®Google Scholar
• Penning-van Beest FJ, van Meegen E, Rosendaal FR, et al. Characteristics of anticoagulant therapy and comorbidity related to overanticoagulation. Thromb Haemost. 2001;86(2):569–574.
   PubMed Web of Science ®Google Scholar
• Cohen J, Sinvani L, Wang JJ, et al. Warfarin quality metrics for hospitalized older adults. TH Open. 2018;2(3):e242–e249.
   PubMedGoogle Scholar
• Xarelto (rivaroxaban) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc.; March 2017.
   Google Scholar
• Eliquis (apixaban) [prescribing information]. New York, NY: Pfizer Inc; July 2016.
   Google Scholar
• Testa S, Prandoni P, Paoletti O, et al. Direct oral anticoagulant plasma levels’ striking increase in severe COVID-19 respiratory syndrome patients treated with antiviral agents: the cremona experience. J Thromb Haemost . 2020;18(6):1320–1323. [published online ahead of print, 2020 Apr 23].
   PubMed Web of Science ®Google Scholar
• Grasselli G, Zangrillo A, Zanella A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the lombardy region, Italy . JAMA. 2020;323(16):1574–1581. [published online ahead of print, 2020 Apr 6]
   PubMed Web of Science ®Google Scholar
• Heart Rhythm Society. UPDATE: general guidance for QTc monitoring in COVID-19 patients. (22 May 2020), https://www.hrsonline.org/COVID19-Challenges-Solutions/hrs-covid-19-task-force-update-april-21-2020
   Google Scholar
• Tisdale JE, Jaynes HA, Kingery JR, et al. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients published correction appears in circ cardiovasc qual outcomes. Circ Cardiovasc Qual Outcomes. 2013;6(4):479–487.
   Google Scholar
• Roden DM, Harrington RA, Poppas A, et al. Considerations for drug interactions on QTc in exploratory COVID-19 (Coronavirus disease 2019) treatment. Circulation. 2020;141(24): [published online ahead of print, 2020 Apr 8]. doi:10.1161/CIRCULATIONAHA.120.047521.
   Web of Science ®Google Scholar
• CREDIBLEMEDS. 2020 [2020 Jun 1]. https://www.crediblemeds.org
   Google Scholar
• Lehmann MH, Hardy S, Archibald D, et al. Sex difference in risk of torsade de pointes with d,l-sotalol. Circulation. 1996;94(10):2535–2541.
   PubMed Web of Science ®Google Scholar
• Køber L, Torp-Pedersen C, McMurray JJ, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med. 2008;358(25):2678–2687.
   PubMed Web of Science ®Google Scholar
• Torp-Pedersen C, Møller M, Bloch-Thomsen PE, et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med. 1999;341(12):857–865.
   PubMed Web of Science ®Google Scholar
• Deedwania PC, Singh BN, Ellenbogen K, et al. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the veterans affairs congestive heart failure survival trial of antiarrhythmic therapy (CHF-STAT). The Department of Veterans Affairs CHF-STAT Investigators. Circulation. 1998;98(23):2574–2579.
   PubMed Web of Science ®Google Scholar
• Kaletra (lopinavir and ritonavir) [prescribing information]. North Chicago, IL: AbbVie Inc; November 2013.
   Google Scholar
• Aimo A, Baritussio A, Emdin M, et al. Amiodarone as a possible therapy for coronavirus infection . Eur J Prev Cardiol. 2020;2047487320919233. [published online ahead of print, 2020 Apr 16].
   Web of Science ®Google Scholar
• Kluwer Wolters. Lexicomp® drug interactions. (30 June 2020), http://online.lexi.com/lco/action/interact
   Google Scholar